Investment Thesis
Bio Green Med Solution is a pre-revenue pharmaceutical company burning significant cash with minimal commercial traction. With only $81K in revenue against $7.3M in operating losses and negative free cash flow of $4.7M, the company is consuming its cash reserves at an unsustainable rate. At current burn rates, the $3.8M cash position provides less than 10 months of runway.
Strengths
- Minimal debt burden with Debt/Equity ratio of 0.00x
- Adequate liquidity ratios (Current Ratio 6.43x, Quick Ratio 5.07x) in the near term
- Total assets of $8.2M provide some balance sheet cushion
Risks
- Critically low revenue of $81K with operating losses of $7.3M indicating failed commercialization or product-market fit
- Negative free cash flow of $4.7M annually will deplete $3.8M cash reserves within 10 months without additional funding
- Extreme profitability deficits: Operating Margin of -9067.9% and Net Margin of -2946.9% indicate fundamental business model failure
- Zero insider filings in last 90 days suggests lack of confidence from management
- No clear path to profitability with massive operating losses relative to minimal revenue
Key Metrics to Watch
- Quarterly revenue trends and commercial milestones
- Monthly cash burn rate and remaining runway
- Operating loss trajectory and cost structure improvements
- Cash position and timeline for next funding requirement
Financial Metrics
Revenue
81.0K
Net Income
-2.4M
EPS (Diluted)
$-2.86
Free Cash Flow
-4.7M
Total Assets
8.2M
Cash
3.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-9,067.9%
Net Margin
-2,946.9%
ROE
-33.6%
ROA
-29.3%
FCF Margin
-5,848.1%
Balance Sheet & Liquidity
Current Ratio
6.43x
Quick Ratio
5.07x
Debt/Equity
0.00x
Debt/Assets
13.0%
Interest Coverage
-1.61x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T23:52:11.282027 |
Data as of: 2025-09-30 |
Powered by Claude AI